NewAmsterdam Pharma Company N.V.
NAMS Healthcare Biotechnology
NewAmsterdam Pharma Company N.V.’s revenue for fiscal 2025 (year ended December 2025) was $22.5 million, down 50.6% from fiscal 2024. In the quarter to June 2026, revenue fell 80.7%, EPS fell 246.7% and free cash flow fell 4.07%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
Follow NAMS
NewAmsterdam Pharma Company N.V. (NAMS) Altman Z-score
NewAmsterdam Pharma Company N.V.'s Altman Z-score for fiscal 2025 is 27.63, in the safe zone (above 2.99).
Altman Z-score, annual
Embed this chart
Annual newest first
| Period | Altman Z-score | Change (points) |
|---|---|---|
| FY2025 | 27.63 | 14.52 |
| FY2024 | 13.11 | 5.68 |
| FY2023 | 7.43 | 3.98 |
| FY2022 | 3.45 | (6.79) |
| FY2022 | 10.24 | — |
How fiscal 2025’s score is made up
| Component | This year | Year before | Result | Points |
|---|---|---|---|---|
| Working capital / total assets | 0.77 | — | 0.92 | |
| Retained earnings / total assets | (0.99) | — | −1.39 | |
| EBIT / total assets | (0.29) | — | −0.97 | |
| Market value of equity / total liabilities | 48.39 | — | 29.03 | |
| Sales / total assets | 0.03 | — | 0.03 | |
| Altman Z-score | Safe zone | 27.63 | ||
| Z″ Variant for non-manufacturing and asset-light companies (drops the sales/assets term, uses book equity) | Safe zone | 8.19 | ||
How the Altman Z-score works
Z = 1.2 × working capital ÷ total assets + 1.4 × retained earnings ÷ total assets + 3.3 × EBIT ÷ total assets + 0.6 × market value of equity ÷ total liabilities + 1.0 × revenue ÷ total assets (Altman, 1968). The market value of equity is the close on the last trading day of the fiscal year times weighted basic shares.
Z″ = 6.56 × working capital ÷ total assets + 3.26 × retained earnings ÷ total assets + 6.72 × EBIT ÷ total assets + 1.05 × book equity ÷ total liabilities (Altman, Hartzell and Peck, 1995), the variant for non-manufacturing and asset-light companies.
| Zone | Z | Z″ |
|---|---|---|
| Safe zone | above 2.99 | above 2.60 |
| Grey zone | 1.81–2.99 | 1.10–2.60 |
| Distress zone | below 1.81 | below 1.10 |
Not worked out for banks, insurers and REITs, whose balance sheets the model does not describe, nor when a figure is missing or there is no share price in the week to the fiscal year end.
Altman Z-score against peers
| Company | Altman Z-score |
|---|---|
| NAMS NewAmsterdam Pharma Company N.V. | 27.6× |
| ADMA ADMA Biologics Inc compare | 20.0× |
| CLDX Celldex Therapeutics, Inc. compare | 14.4× |
| AUPH Aurinia Pharmaceuticals Inc compare | 7.9× |
| BEAM Beam Therapeutics Inc. compare | 5.4× |
| ZLAB Zai Lab Limited Unsponsored ADR compare | −0.2× |
| SLS SELLAS Life Sciences Group, Inc. compare | −16.8× |
| PGEN Precigen, Inc. compare | −16.9× |
| MBX MBX Biosciences, Inc. compare | — |
What Altman Z-score is
The Altman Z-Score weighs working capital, retained earnings, operating profit, market value and sales against assets and debts to gauge the risk of distress.
1.2 × working capital ÷ total assets + 1.4 × retained earnings ÷ total assets + 3.3 × EBIT ÷ total assets + 0.6 × market value of equity ÷ total liabilities + 1.0 × revenue ÷ total assets